Lates News

The Food and Drug Administration (FDA) stated that a television commercial for Novo Nordisk's (NVO.N) new weight loss drug contains "false or misleading" claims about the weight loss effects of the drug, exacerbating the challenges faced by the pharmaceutical company recently. The FDA said that the TV commercial "misleadingly" implies that the oral form of Wegovy has advantages over other weight loss medications. In a letter to Novo Nordisk on February 5, the agency specifically questioned the claims of "living lightly" and "bright future" that appeared in the advertisement. "Furthermore, these claims misleadingly imply benefits beyond actual weight loss, such as emotional relief, reduced psychological burden, bringing hope or direction to patients' lives, positioning the drug as a solution to broader life challenges rather than a treatment for a specific disease," the FDA said.